Weatherly Asset Management L. P. bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,416 shares of the biopharmaceutical company’s stock, valued at approximately $412,000.

Other large investors have also recently modified their holdings of the company. Garrett Wealth Advisory Group LLC bought a new stake in shares of Bristol-Myers Squibb during the third quarter worth $26,000. Savior LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at $39,000. Lenox Wealth Advisors LLC grew its position in Bristol-Myers Squibb by 555.7% in the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. grew its position in Bristol-Myers Squibb by 101.2% in the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 327 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. grew its position in Bristol-Myers Squibb by 52.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 230 shares in the last quarter. 83.35% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on BMY. UBS Group raised their target price on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. Morgan Stanley started coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 22nd. They set an “equal weight” rating and a $60.00 target price for the company. Mizuho started coverage on shares of Bristol-Myers Squibb in a research report on Monday, November 25th. They set a “buy” rating on the stock. Gabelli started coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, November 27th. They set a “buy” rating on the stock. Finally, Wolfe Research set a $66.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $61.69.

BMY stock traded down $1.07 during mid-day trading on Friday, hitting $65.80. The stock had a trading volume of 897,843 shares, compared to its average volume of 12,153,140. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $68.34. The firm has a market capitalization of $109.86 billion, a P/E ratio of 18.96, a P/E/G ratio of 0.81 and a beta of 0.73. The firm has a fifty day simple moving average of $64.02 and a 200 day simple moving average of $53.87.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The firm had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. During the same period last year, the firm earned $1.09 EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. As a group, equities analysts expect that Bristol-Myers Squibb Co will post 4.34 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Thursday, January 2nd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 annualized dividend and a dividend yield of 2.74%. Bristol-Myers Squibb’s payout ratio is 45.23%.

In related news, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the sale, the senior vice president now directly owns 74,471 shares in the company, valued at $4,219,526.86. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.